The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its future within the broader sector now presents questions about potential yields . Generic versions are undercutting market share, leading to anxieties that investing in companies significantly dependent to Viagra's once-dominant standing could